{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-069941","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.234692+00:00","generated_at":"2026-05-31T08:54:06.992136+00:00","sec_items":["3.03","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cadrenal Therapeutics announces 1-for-15 reverse stock split effective Aug 20, 2024","bullets":["Reverse stock split ratio set at 1-for-15; effective at 12:01 a.m. ET on August 20, 2024.","Outstanding shares reduced from ~16M to ~1.1M; no fractional shares; cash paid in lieu.","New CUSIP number 127636 207; stock continues trading under CVKD on Nasdaq.","Split intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.","Proportional adjustments made to equity awards, warrants, and exercise prices."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-069941","json":"https://secwatch.observer/filing/0001213900-24-069941.json","markdown":"https://secwatch.observer/filing/0001213900-24-069941.md","text":"https://secwatch.observer/filing/0001213900-24-069941.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/0001213900-24-069941-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024069941/ea021156901-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:54:06.992136+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}